RxDoctor Payments Data

John Gooch, MD

Ophthalmology · The Villages, FLNPI 1417935511

Payments from drug & device makers

$1,910in general payments, 2019–2025

Across 76 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$450
  • Regeneron Healthcare Solutions, Inc.$253
  • Novartis$250
  • AbbVie$165
  • Sun Pharmaceutical Industries Inc.$130
  • Tarsus Pharmaceuticals, Inc.$112
  • plus $550 from 13 others

What the payments were for

  • Food & beverage$1,89299%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,910 in reported general payments places this provider in the 45th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$1,020,923
Medicare patients
3,999
Services billed
9,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine137$149,583
RocklatanNetarsudil Mesylat/Latanoprost122$104,153
LumiganBimatoprost113$81,569
XiidraLifitegrast49$63,290
RhopressaNetarsudil Mesylate44$34,820
Latanoprost2,262$34,017
Cyclosporine42$29,363
Brimonidine Tartrate746$27,808
SimbrinzaBrinzolamide/Brimonidine Tart62$20,507
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol89$18,021
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat807$13,549
CombiganBrimonidine Tartrate/Timolol23$13,400
Brinzolamide40$8,394
Dorzolamide Hcl389$8,332
VyzultaLatanoprostene Bunod12$8,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$165$244,552273 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$36$138,973166 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$18$71,52161 claims
AlconSimbrinza, Azopt$78$27,52774 claims
NovartisIlevro$250$4,33012 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$70$2,90012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →